MARKET

MGX

MGX

Metagenomi Therapeutics, Inc
NASDAQ
1.205
-0.015
-1.23%
After Hours: 1.205 0 0.00% 16:10 07/24 EDT
OPEN
1.240
PREV CLOSE
1.220
HIGH
1.240
LOW
1.200
VOLUME
65.89K
TURNOVER
--
52 WEEK HIGH
3.950
52 WEEK LOW
1.130
MARKET CAP
45.36M
P/E (TTM)
-0.5247
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MGX last week (0713-0717)?
Weekly Report · 5d ago
PROLYNX NAMES SIMON HARNEST AS CHIEF FINANCIAL OFFICER AND AMER MIRZA, PHD, AS CHIEF SCIENTIFIC OFFICER AS IT ADVANCES MULTI-PROGRAM OBESITY AND METABOLIC DISEASE PORTFOLIO
Reuters · 07/15 12:00
Weekly Report: what happened at MGX last week (0706-0710)?
Weekly Report · 07/13 10:21
Metagenomi Price Target Cut to $5.00/Share From $7.00 by Chardan Capital
Dow Jones · 07/07 11:08
Metagenomi Is Maintained at Buy by Chardan Capital
Dow Jones · 07/07 11:08
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5
Benzinga · 07/07 10:59
Metagenomi transferred with a Buy at Chardan
TipRanks · 07/07 10:40
Weekly Report: what happened at MGX last week (0629-0703)?
Weekly Report · 07/06 10:25
More
About MGX
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. It is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. It focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.

Webull offers Metagenomi Therapeutics Inc stock information, including NASDAQ: MGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGX stock methods without spending real money on the virtual paper trading platform.